Back to today’s briefing

Story perspectives

Novo Nordisk Launches $499 Ozempic Cash-Pay Option for Diabetes

8/18/2025

41 3

Summary

Story summary

Novo Nordisk introduced a cash-pay option for Ozempic at $499 monthly, reducing costs for uninsured Type 2 diabetes patients.
This offer is accessible via NovoCare and GoodRx, targeting gaps in existing insurance coverage.
Novo Nordisk's shares increased following Wegovy's FDA approval for metabolic dysfunction-associated steatohepatitis (MASH).
Wegovy is the first GLP-1 treatment approved for MASH, strengthening its market position.

1 of 1

Story summary

Novo Nordisk introduced a cash-pay option for Ozempic at $499 monthly, reducing costs for uninsured Type 2 diabetes patients.
This offer is accessible via NovoCare and GoodRx, targeting gaps in existing insurance coverage.
Novo Nordisk's shares increased following Wegovy's FDA approval for metabolic dysfunction-associated steatohepatitis (MASH).
Wegovy is the first GLP-1 treatment approved for MASH, strengthening its market position.